Skip to main content

Main menu

  • Home
  • Articles
    • Current issue
    • ERJ Early View
    • Archive
  • About
    • About continuous publication
    • Journal information
    • Editorial Board
    • CME
    • Press office
    • Permissions and reprints
    • Advertising
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • For readers
    • Alerts
    • Subjects
    • Podcasts
    • RSS
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Articles
    • Current issue
    • ERJ Early View
    • Archive
  • About
    • About continuous publication
    • Journal information
    • Editorial Board
    • CME
    • Press office
    • Permissions and reprints
    • Advertising
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • For readers
    • Alerts
    • Subjects
    • Podcasts
    • RSS
  • Subscriptions

MDR-TB and XDR-TB: drug resistance and treatment outcomes

G. B. Migliori, G. Sotgiu, M. D'Arcy Richardson, R. Centis, A. Facchini, G. Guenther, A. Spanevello, C. Lange
European Respiratory Journal 2009 34: 778-779; DOI: 10.1183/09031936.00059409
G. B. Migliori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Sotgiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. D'Arcy Richardson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Centis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Facchini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Guenther
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Spanevello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Lange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

We read with interest the study by Hwang et al. 1, which continues the discussion on factors associated with poor outcomes in the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

The subject is quite topical, as TB programmes and clinicians are searching for solutions to treat MDR/XDR-TB most effectively. Recently published studies and a systematic review have shown that XDR-TB is associated with higher probability of failure and death, and lower probability of treatment success than MDR-TB 2–7. The XDR-TB-defining drugs have been studied to evaluate their role in determining successful outcomes in MDR/XDR-TB cases (XDR-TB is defined as resistance to at least isoniazid and rifampicin (MDR-TB) plus to any fluoroquinolone and at least one of three injectable anti-TB drugs (amikacin, capreomycin or kanamycin) 2, 3).

Hwang et al. 1 re-analysed data from previously published studies, including 197 MDR/XDR-TB cases in HIV-negative individuals (42 of them affected by XDR-TB) who were enrolled in a university hospital in Seoul, South Korea. They found that resistance to additional first-line anti-TB drugs (other than isoniazid and rifampicin) or to injectable drugs was not associated with higher odds for poor treatment outcomes in patients with MDR-TB. However, streptomycin resistance was associated with poor outcomes in XDR-TB cases, with high OR (12.05, 95% CI 1.48–98.38). Hwang et al. 1 were not able to confirm our own previous findings 4, which reported a favourable outcome for cases with MDR-TB strains sensitive to kanamycin or capreomycin. Hwang et al. 1 call for larger studies to evaluate the role of injectables in MDR/XDR-TB treatment.

Recently, different classes of XDR-TB-defining drugs have been studied systematically by TBNET to evaluate their role in determining successful outcomes in MDR/XDR-TB cases. After demonstrating that XDR-TB patients have a higher risk of death and failure than those with MDR-TB 5–7, we found evidence that: 1) resistance to additional first-line drugs (other than isoniazid and rifampicin) is a predictor of adverse outcomes 7; and 2) resistance to fluoroquinolones contributes to increased risk of death and failure in MDR-TB cases 8. Additionally, the role of second-line injectable drugs was studied using logistic regression analysis; we found that resistance to capreomycin was the only independent variable significantly associated with unfavourable outcomes in MDR/XDR-TB (OR 3.51, 95% CI 1.67–7.36; p = 0.001), while resistance to amikacin (OR 1.76, 95% CI 0.91–3.39; p = 0.09) and kanamycin (OR 1.57, 95% CI 0.96–2.57; p = 0.07) achieved borderline significance 8.

Following the report by Hwang et al. 1, we attempted to verify their findings using the TBNET cohort. The cohort consisted of 4,583 culture-confirmed cases diagnosed consecutively by the TB clinical reference centres in Estonia (Tallin and Tartu), Germany (Borstel, Grosshansdorf and Bad-Lippspringe), Italy (Sondalo, Milan and Rome) and the Russian Federation (Archangels Oblast). Amongst the cohort, 240 MDR-TB and 48 XDR-TB cases had a definitive outcome recorded (treatment success, died, failure). The standard definitions for treatment outcome in MDR-TB were used 9. Drug susceptibility testing (DST) for first-line (isoniazid, rifampicin, ethambutol and streptomycin) and second-line anti-TB drugs was performed according to World Health Organization (WHO) recommendations by quality-assured laboratories and retested at WHO’s Supranational Reference Laboratories in Rome and Milan, Borstel, Stockholm (Sweden), and Oslo (Norway) 4, 8. In all countries, regimens to treat MDR/XDR-TB cases were tailored to the DST results according to WHO recommendations. Within the cohort, the proportion of HIV-seropositive patients was 4.7% 4.

Data from all culture-confirmed MDR/XDR-TB cases with a definitive outcome recorded were re-analysed 4 to compare with the findings of Hwang et al. 1. Logistic regression analysis was performed in order to evaluate the ORs associated with negative treatment outcomes (failure, death), comparing patients who were susceptible to additional first-line or injectable drugs versus those with different patterns of resistance to the above-mentioned drugs, respectively.

The results are reported in table 1⇓ according to the format used in the study by Hwang et al. 1. In contrast to their findings, we found no significant risk factor for negative treatment outcome using univariate analysis, even after adjusting for the main confounding variables. Streptomycin resistance was not associated with negative treatment outcomes in either the overall MDR/XDR-TB cohort (unadjusted and adjusted ORs were 1.07 with 95% CI 0.4–2.9 and 1.13 with 95% CI 0.32–4.1, respectively) or in XDR-TB cases specifically (unadjusted and adjusted ORs were 1.19 with 95% CI 0.1–20.2 and 0.43 with 95% CI 0.66–15, respectively).

View this table:
  • View inline
  • View popup
Table 1—

Impact of the various combinations of first-line and injectable drug resistance on negative treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB)

MDR-TB and resistance to any fluoroquinolone plus one second-line injectable drug was in fact the only combination of drug resistance significantly associated with an increased risk of death or failure (unadjusted and adjusted ORs were 2.6, 95% CI 1.38–4.88 and 2.9, 95% CI 1.51–5.63, respectively; table 1⇑).

Our findings suggest that streptomycin resistance was not associated with death and failure in this European cohort. A number of factors may have contributed to the differences reported. Methodological differences (e.g. number of drugs tested for resistance, sample sizes) and data limitations of both retrospective studies make a clear explanation for the different outcomes of the analyses difficult to discern. From a clinical perspective, the mechanism whereby streptomycin resistance alone would produce poorer treatment outcomes is unclear and warrants additional exploration.

Although results from the various published studies on MDR/XDR-TB treatment outcomes do not leave us with a clear clinical direction to follow, the underlying messages are the same: MDR/XDR-TB is difficult to decode with the limited information available based on retrospective data from small cohorts 2, 10. Well-designed, randomised, prospective studies are necessary to provide more definitive answers to the treatment questions that are still pending, the most burning being which regimens can offer MDR/XDR-TB patients the best chance of cure 2.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Hwang SS, Kim HR, Kim HJ, et al. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J 2009;33:581–585.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009;33:871–881.
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?. Eur Respir J 2007;29:423–427.
      OpenUrlFREE Full Text
    4. ↵
      Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008;31:1155–1159.
      OpenUrlAbstract/FREE Full Text
    5. ↵
      Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 2007;13:780–782.
      OpenUrlPubMedWeb of Science
    6. Migliori GB, Lange C, Girardi E, et al. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin Infect Dis 2008;46:958–959.
      OpenUrlFREE Full Text
    7. ↵
      Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007;30:623–626.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. Eur Respir J 2008;31:904–905.
      OpenUrlFREE Full Text
    9. ↵
      Laserson K, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640–645.
      OpenUrlPubMedWeb of Science
    10. ↵
      Migliori GB, Richardson MD, Lange C. Of blind men and elephants: making sense of extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1000–1001.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 34 Issue 3 Table of Contents
    European Respiratory Journal: 34 (3)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    MDR-TB and XDR-TB: drug resistance and treatment outcomes
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    MDR-TB and XDR-TB: drug resistance and treatment outcomes
    G. B. Migliori, G. Sotgiu, M. D'Arcy Richardson, R. Centis, A. Facchini, G. Guenther, A. Spanevello, C. Lange
    European Respiratory Journal Sep 2009, 34 (3) 778-779; DOI: 10.1183/09031936.00059409

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    MDR-TB and XDR-TB: drug resistance and treatment outcomes
    G. B. Migliori, G. Sotgiu, M. D'Arcy Richardson, R. Centis, A. Facchini, G. Guenther, A. Spanevello, C. Lange
    European Respiratory Journal Sep 2009, 34 (3) 778-779; DOI: 10.1183/09031936.00059409
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Chronic breathlessness: re-thinking the symptom
    • Wheeze phenotypes in preschool children
    • NSCLC patients with preoperative clinical N1 disease
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • CME
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • Collections
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Fax: +44 114 266 5064
    Email: info@ersj.org.uk

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2018 by the European Respiratory Society